SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust ($SLV) is experiencing intense bullish momentum, driven by spot silver prices reaching new all-time highs with significant premiums reported in Shanghai. This rally is fueled by tightening global supply due to upcoming Chinese export restrictions, alongside booming industrial demand from EV batteries, solar, and AI data centers, leading many to anticipate a massive "silver squeeze" and a re-rating of its value. While bulls foresee further exponential gains, some community members anticipate a near-term pullback after its rapid ascent.

Polkadot is a platform that allows diverse blockchains to transfer messages, including value, in a trust-free fashion; sharing their unique features while pooling their security. In brief, Polkadot is a scalable heterogeneous multi-chain technology.  Polkadot is heterogeneous because it is entirely flexible and makes no assumption about the nature or structure of the chains in the network. Even non-blockchain systems or data structures can become parachains if they fulfill a set of criteria.  Polkadot may be considered equivalent to a set of independent chains (e.g. a set containing Ethereum, Ethereum Classic, Namecoin and Bitcoin) except with important additions: pooled security and trust-free interchain transactability.  Many of the native parachains of Polkadot will be written using a Polkadot Runtime Environment SDK (e.g. Parity Technologies' Substrate).

Polkadot

Polkadot is trending amidst significant network upgrades, including the rollout of Polkadot 2.0 featuring elastic scaling, a new supply cap for DOT with halving emissions, and a migration of governance and staking to its Asset Hub chain. Community sentiment is notably divided, with proponents viewing these tokenomic shifts as strong bullish catalysts for long-term growth and others expressing deep skepticism regarding past performance and future prospects. These developments also unfold alongside discussions of its interoperability within the broader crypto ecosystem and ongoing dialogues around potential crypto ETF approvals.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors celebrate the recent FDA approval of YARTEMLEA, the first and only treatment for a life-threatening post-transplant complication, sparking a fervent discussion on its potential. The community believes the stock is significantly undervalued, pointing to a strategic partnership with Novo Nordisk and a strong pipeline, fueling speculation of a massive short squeeze and potential buyout. Anticipation is high for further details on commercialization plans and pricing, with many urging long-term holds.

Direxion Shares ETF Trust - Direxion Daily S&P 500 Bull 3X Shares

Direxion Daily S&P 500 Bull 3X Shares

Direxion Daily S&P 500 Bull 3X Shares is trending as the broader S&P 500 index recently achieved new record highs, fueling fervent bullish sentiment. The community is actively debating whether this marks the continuation of an upward rally, prompting many to buy dips and leverage for amplified gains. While economic indicators and discussions around central bank policies add context, traders are keenly focused on riding the market's momentum.

abrdn ETF - abrdn Physical Silver Shares ETF

SIVR is trending as silver prices achieve significant highs, driven by strong investor demand for safe-haven assets and expectations of loosening monetary policy. The community is actively discussing silver's breakout, citing perceived undervaluation, tightening supply, and increasing industrial demand amid global economic uncertainties. Many anticipate continued upward movement, seeing silver as a critical hedge against inflation and a weaker dollar.

A community-driven memecoin created to protect and empower crypto users, CTOs, and low-marketcap gems. Our ecosystem features weekly crypto talks/hosting services, a “Most Wanted" scam tracker, and a "Portfolio" with partnered projects. We help others succeed through long-term partnerships and services.   Weekly Hosting: a weekly hosting service where the team and community come together to talk about crypto and project updates. We will invite guests from rugged projects who want to talk/share insight, invite CTO/low market cap projects to come speak about what they are doing, and give dedicated time for partnered projects to speak on updates for our listeners.   Portfolio: a webpage designated to embrace CTOs or smaller cap projects with an established following.  Partnered projects commit to a discussed rate to help fuel growth of the RCON token and their own, through a structured revenue distribution model (detailed below).  Tokens will be held as long as the partnered project remains active.  12.5% buys RCON coin and burns 12.5% sent to RCON marketing wallet 12.5% used for LP/Pairing [RCON and partnered token] on ORCA 12.5% dedicated to community outreach 50% buys and holds initial value of partnered token  Most Wanted: a webpage designated to expose chronic offenders / scammers / ruggers.  Our project can help those navigate the cryptocurrency space safely.

Recon Raccoon

RCON CRYPTO is gaining attention as the community actively discusses significant portions of its token supply being locked, earmarked for future Centralized Exchange listings and long-term team vesting. Investors are highlighting the project's committed team and its detailed vision as pivotal factors driving interest and future potential.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony is a prominent talking point as the market reacts to escalating global tensions and China's increased control over critical mineral exports. Investors are keenly focused on UAMY's established role as a key domestic supplier, particularly for military-grade antimony, and its ongoing capacity expansion to meet growing strategic demand amidst skepticism surrounding emerging competitors.

xCellar is a DeFi protocol powered by the Fawkes Formula, providing untraceable and secure transactions on the blockchain. It's designed to give users complete financial privacy and control over their assets. The Fawkes Formula is our proprietary security protocol that forms the core of xCellar's untraceable transaction system. It utilizes advanced zero-knowledge proofs and cryptographic techniques to ensure complete anonymity.

Xcellar

Xcellar ($XCL) is trending amid discussions of its new protocol updates nearing completion and the approaching conclusion of the Sentinel token presale, which is expected to drive supply burns and reward distribution. The community is actively highlighting XCL's resilient performance, significant past gains, and its core focus on providing anonymous transactions and passive income opportunities for holders. Many investors are viewing recent price pullbacks as opportune entry points, anticipating substantial long-term growth within the privacy-focused crypto sector.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending with highly polarized sentiment, as its dedicated community anticipates a significant upward move and a 'Christmas rally', while a vocal group expresses skepticism, labeling it a 'scam' and noting its extended period of underperformance. The conversation actively centers on token burning initiatives and comparisons to other meme coins, reflecting broader market speculation on altcoin viability.

abrdn ETF - abrdn Physical Platinum Shares ETF

abrdn Physical Platinum Shares ETF (PPLT) is experiencing a notable surge in trading volume and price, fueled by strong community sentiment anticipating a significant breakout. Discussions highlight platinum's projected supply deficits, rising industrial demand for automotive catalysts and green energy, and its perceived undervaluation relative to gold. This bullish outlook is further intensified by geopolitical risks affecting key mining regions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NVNO's Shares Decline on Unfavorable FDA Review Outcome for VenoValve

enVVeno Medical shares plunge after the FDA rejects its VenoValve PMA, citing insufficient trial data and safety concerns tied to the surgical procedure.

Medical device company enVVeno Medical Corporation (NVNO) on Wednesday announced that the U.S. Food &amp; Drug Administration (FDA) has refused to approve its application for its lead product, VenoValve, a surgical replacement venous valve for treating severe deep chronic venous insufficiency (CVI).Following the announcement, NVNO shares plunged 71% by Wednesday afternoon, at the time of writing.Severe deep chronic venous insufficiency (CVI) is a long-term condition where the veins in the legs have difficulty returning blood to the heart, leading to blood pooling and various symptoms like swelling, aching, and skin changes. This occurs primarily due to damaged or weakened valves within the deep leg veins.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVNO">NVNO</a> rose from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while retail chatter rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:563/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_20_at_12_41_02_PM_png_bca2208bb7.webp" alt="NVNO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Aug. 20, 2025 | Source: Stocktwits" width="563" height="61"><figcaption>NVNO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Aug. 20, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for the company renegotiating with the FDA.<stembedurl>https://stocktwits.com/Flying_Trader2/message/625960642</stembedurl>Another user said that they see no value in the company with the VenoValve rejection.<stembedurl>https://stocktwits.com/kmx_swing/message/625941525</stembedurl>The FDA <a target="_blank" rel="noopener noreferrer nofollow" href="https://envveno.com/envveno-receives-not-approvable-letter-from-the-fda-for-the-venovalve/">said</a> in a letter that it completed its review of the company’s application for VenoValve but has decided that it is unable to approve it in its current form. The agency said that data generated by the company for the application was not sufficient on its own to determine the favorability of the benefit-risk profile for VenoValve.The FDA also raised concerns about bias and the possibility that clinical improvement occurred as a result of the patients being enrolled in a study. The agency further raised safety concerns, which were attributed to the VenoValve open surgical procedure, and which required re-hospitalizations.CEO Robert Berman said that the company is disappointed by the FDA’s decision and highlighted that a high percentage of patients in a study showed significant clinical improvement after receiving VenoValve. Berman added that the company will continue to work with the FDA on new criteria to demonstrate the safety and effectiveness of the device.The firm’s next steps may include a meeting with the FDA to discuss requirements for a potential resubmission of the VenoValve or appeal of the decision, along with appropriate next steps.NVNO stock is down by 59% this year and by about 77% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-says-tesla-model-yl-might-not-ever-come-to-us-markets/chsitLlRdhq">Elon Musk Said Tesla’s Model Y L Might Not Ever Come To US Markets – Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Medical Device Stock Just Plunged A Whopping 71% Today – Do You Own It?

enVVeno Medical Corporation CEO Robert Berman said that the company will continue to work with the FDA on new criteria to demonstrate the safety and effectiveness of its VenoValve device. 

Equity

This account has been verified as an official NVNO representative.

Verified Account

enVVeno Medical

enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. Its products include VenoValve and enVVe. The company was founded by Norman Jaffe on December 22, 1999 and is headquartered in Irvine, CA.

NVNO
enVVeno Medical Corporation

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NVNO News

NVNOenVVeno Medical Corporation